Predict your next investment

Profectus BioSciences company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
profectusbiosciences.net

See what CB Insights has to offer

Founded Year

2003

Stage

Grant - III | Alive

Total Raised

$29.04M

About Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Profectus BioSciences Headquarter Location

6411 Beckley Street Suite N201

Baltimore, Maryland, 21224,

United States

443-743-1100

Latest Profectus BioSciences News

Aurobindo Pharma working on COVID-19 vaccine; shortlisted for BIRAC funding

Aug 7, 2020

"During the year (FY20), we have further strengthened our presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines. Using those R&D assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19," it said. PTI × Aurobindo Pharma Limited is working on developing several viral vaccines including one for COVID-19 even as the candidate was approved for funding by the Department of BioTechnology, the company said in its latest annual report. "During the year (FY20), we have further strengthened our presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines. Using those R&D assets, the team is working on developing several viral vaccines, including a vaccine for COVID-19," it said. In November 2019, Aurobindo Pharma said its subsidiary Auro Vaccines LLC entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around Rs 80 crore) with potential earn-outs on achieving certain milestones. "Our vaccine candidate underwent an evaluation by BIRAC (Biotechnology Industry Research Assistance Council, Department of BioTechnology). BIRAC has evaluated our platform extensively and we have been informed that our vaccine has been shortlisted by BIRAC for funding initial development up," the city-based drug maker said in the annual report. related news The global market size of the product is USD 6.2 billion. The company has successfully completed the Phase-I and Phase II studies. Phase-III clinical study is expected to be initiated by December 2020. The final product would be launched by the end of FY22, Aurobindo said. "The acquisition (of Profectus BioSciences) will also lead to the enhancement of our R&D capabilities and expertise in developing new vaccines from basic discovery to FDA approved products. As part of our commitment to patient needs, we have started working on developing a vaccine for COVID- 19," the report said. Aurobindo is setting up manufacturing facilities for orals in China, injectables and other routes of administration like patches, topicals, inhalers, among others in India and in the USA. Also, its biosimilars (Unit XVII) and vaccines facilities (Unit XVIII) are ready for commercialisation. The COVID-19 pandemic impacted select business segments like generic injectables due to a decline in in- patient volumes and out-patient footfalls in the hospitals during the last fiscal. However, the muted growth was offset by volume improvement in other businesses. First Published on Aug 7, 2020 11:42 am

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Profectus BioSciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Profectus BioSciences is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

I

Infectious Disease

2,330 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Profectus BioSciences Patents

Profectus BioSciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2015

4/3/2018

Molecular biology, RNA, Gene expression, Transcription factors, DNA

Grant

Application Date

2/27/2015

Grant Date

4/3/2018

Title

Related Topics

Molecular biology, RNA, Gene expression, Transcription factors, DNA

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.